Tokushima University / Educator and Researcher Directory --- Shinomiya, Ryo

Search:

Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 医学域 ⟩ Endwed Collaborative Research ⟩ Contribution ⟩ Department of General Medicine and Community Health Science ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Yasuyuki Okada, Yasushi Sato, Ryo Shinomiya, Takanori Miyake, Taku Takahashi, Reiko Yokoyama, Yasuhiro Mitsui, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Yutaka Kawano and Tetsuji Takayama : Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment., International Journal of Clinical Oncology, Online ahead of print., 2025. (Summary) Liposomal irinotecan + fluorouracil/leucovorin (nal-IRI + 5FU/LV) is commonly used as a second- or later-line treatment for pancreatic ductal adenocarcinoma (PDAC) and offers survival benefits. However, its efficacy and safety in patients previously treated with FOLFIRINOX, which includes irinotecan, remain unclear. We evaluated the efficacy and safety of nal-IRI + 5FU/LV in patients with unresectable PDAC who received previous FOLFIRINOX therapy and those who did not. This retrospective observational study included 42 patients with PDAC who were treated with nal-IRI + 5FU/LV (October 2020-November 2023). Patients were grouped based on prior FOLFIRINOX treatment. The progression-free survival (PFS) in patients who previously received modified FOLFIRINOX (mFFX) therapy was shorter than that in patients who did not (2.5 vs. 3.5 months, P = 0.07). When patients with greater than- and less than the cut-off value of irinotecan-free interval (IFI) were classified into the long and short IFI groups, respectively, PFS was significantly longer in the long-IFI group than that in the short IFI group (4.0 vs. 2.1 months, P = 0.01). Moreover, the C-reactive protein/albumin ratio (CAR) was also a significant predictor of PFS (P = 0.03). Furthermore, both factors were found to be independent factors influencing PFS in the univariate Cox regression analysis (P = 0.02 and P = 0.04). Nal-IRI + 5FU/LV therapy may be a safe and effective option as a second- or later-line treatment, particularly for patients who have not previously received mFFX therapy. For patients who received prior mFFX exposure, a longer IFI and lower CAR may indicate greater potential benefit, thus aiding in more personalized treatment approaches. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-024-02677-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40266453 ● Search Scopus @ Elsevier (PMID): 40266453 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-024-02677-y (DOI: 10.1007/s10147-024-02677-y, PubMed: 40266453)

Proceeding of Domestic Conference:

1.	Ryo Shinomiya, Toshiya Okahisa, 米田健一, Tatsunao Sueuchi, 大木元彩夏, Reiko Yokoyama, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, 岡本耕一, Masahiro Sogabe, Masaki Oono and Tetsuji Takayama : 多数部位同時腸音解析システムを用いた腸音測定部位の最適化．, 第123回日本消化器病学会四国支部例会, 高知., Jun. 2025.
2.	中嶋健吾, Toshiya Okahisa, Ryo Shinomiya, Tatsunao Sueuchi, Miwako Kagawa, Takeshi Mitsuhashi, Hiroyuki Ueda, Masahiro Sogabe, 宮本弘志, 佐藤康史, Masaki Oono and Tetsuji Takayama : 腸音解析による腸運動の評価．, 第123回日本消化器病学会四国支部例会, 高知., Jun. 2025.
3.	大塚真人, 佐藤康史, Ryo Shinomiya, Takeshi Mitsuhashi, 吉本貴則, 川口智之, 岡本耕一, Tetsu Tomonari, 河野豊, Masahiro Sogabe, 宮本弘志 and 高山哲治 : FGFR2遺伝子異常を認めた治療抵抗性進行胃癌に対してpemigatinibが著効した一例., 第120回日本消化器病学会四国支部例会, 高知., Dec. 2023.